Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions

被引:9
作者
Li, Jian-ri [1 ,3 ]
Yang, Chi-rei [2 ]
Cheng, Chen-li [1 ]
Ho, Hao-chung [1 ]
Chiu, Kun-yuan [1 ]
Su, Chung-Kuang [1 ]
Chen, Wen-Ming [1 ]
Wang, Shian-Shiang [1 ]
Chen, Chuan-Shu [1 ]
Yang, Cheng-Kuang [1 ]
Ou, Yen-chuan [1 ]
机构
[1] Taichung Vet Gen Hosp, Div Urol, Dept Surg, Taichung 407, Taiwan
[2] China Med Univ Hosp, Dept Urol, Taichung, Taiwan
[3] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung, Taiwan
关键词
Hand-foot skin reactions; Heparin; Multikinase inhibitor; Renal cell carcinoma; RENAL-CELL CARCINOMA; PHASE-II; SORAFENIB; SUNITINIB; TRIAL;
D O I
10.1007/s00520-012-1693-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study is to evaluate the efficacy of a protocol including topical heparin therapy for hand-foot skin reactions (HFSR) during multikinase (MKI) treatment. We prospectively collected 26 patients who had HFSRs during treatment with the MKIs, sunitinib, sorafenib, or axitinib. The age distribution ranged from 46 to 87 years, with a mean of 66 years. The distribution of HFSR severity was 12 patients with grade 1, 12 with grade 2, and 2 with grade 3. A heparin-containing topical ointment treatment, combined with hand-foot shock absorbers and skin moisturizers, was used at the lesion sites. Changes in the grade of HFSR, MKI dosage, and interruptions of MKI therapy were recorded. The results showed that 66.7 % of grade 1 patients were cured of disease, 83.3 % of grade 2 patients had improved symptoms, and both grade 3 patients (100 %) had improved symptoms and were downgraded to grade 2. Four (15.4 %) patients required reduction of MKI dosage, but there were no treatment interruptions or dropouts. Our protocol is beneficial in promoting resolution of HFSRs induced by MKIs. Further validation in large control studies should be investigated.
引用
收藏
页码:907 / 911
页数:5
相关论文
共 23 条
[1]   Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma [J].
Bhojani, Naeem ;
Jeldres, Claudio ;
Patard, Jean-Jacques ;
Perrotte, Paul ;
Suardi, Nazareno ;
Hutterer, Georg ;
Patenaude, Francois ;
Oudard, Stephane ;
Karakiewicz, Pierre I. .
EUROPEAN UROLOGY, 2008, 53 (05) :917-930
[2]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[3]   Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis [J].
Chu, David ;
Lacouture, Mario E. ;
Weiner, Elizabeth ;
Wu, Shenhong .
CLINICAL GENITOURINARY CANCER, 2009, 7 (01) :11-19
[4]   Toxicities of Targeted Therapy and Their Management in Kidney Cancer [J].
Di Lorenzo, Giuseppe ;
Porta, Camillo ;
Bellmunt, Joaquim ;
Sternberg, Cora ;
Kirkali, Ziya ;
Staehler, Michael ;
Joniau, Steven ;
Montorsi, Francesco ;
Buonerba, Carlo .
EUROPEAN UROLOGY, 2011, 59 (04) :526-540
[5]   Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era [J].
Di Lorenzo, Giuseppe ;
Autorino, Riccardo ;
Sternberg, Cora N. .
EUROPEAN UROLOGY, 2009, 56 (06) :959-971
[6]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[7]   Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma [J].
Escudier, Bernard ;
Szczylik, Cezary ;
Hutson, Thomas E. ;
Demkow, Tomasz ;
Staehler, Michael ;
Rolland, Frederic ;
Negrier, Sylvie ;
Laferriere, Nicole ;
Scheuring, Urban J. ;
Cella, David ;
Shah, Sonalee ;
Bukowski, Ronald M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1280-1289
[8]   Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies [J].
Hutson, Thomas E. ;
Figlin, Robert A. ;
Kuhn, John G. ;
Motzer, Robert J. .
ONCOLOGIST, 2008, 13 (10) :1084-1096
[9]   Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib [J].
Lee, W. J. ;
Lee, J. L. ;
Chang, S. E. ;
Lee, M. W. ;
Kang, Y. K. ;
Choi, J. H. ;
Moon, K. C. ;
Koh, J. K. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) :1045-1051
[10]   Sorafenib in advanced hepatocellular carcinoma [J].
Llovet, Josep M. ;
Ricci, Sergio ;
Mazzaferro, Vincenzo ;
Hilgard, Philip ;
Gane, Edward ;
Blanc, Jean-Frederic ;
Cosme de Oliveira, Andre ;
Santoro, Armando ;
Raoul, Jean-Luc ;
Forner, Alejandro ;
Schwartz, Myron ;
Porta, Camillo ;
Zeuzem, Stefan ;
Bolondi, Luigi ;
Greten, Tim F. ;
Galle, Peter R. ;
Seitz, Jean-Francois ;
Borbath, Ivan ;
Haussinger, Dieter ;
Giannaris, Tom ;
Shan, Minghua ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Bruix, Jordi .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390